+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer



Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer



Future Oncology 6(2): 201-207



We conducted a systematic review to estimate efficacy and safety of ixabepilone plus capecitabine compared with capecitabine alone for patients of anthracycline- and/or taxane-resistant metastatic breast cancer. PubMed, Cochrane Library, EMBASE, ClinicalTrials.gov and other databases were searched. Randomized controlled trials containing ixabepilone plus capecitabine for anthracycline- and/or taxane-resistant metastatic breast cancer were eligible. Studies were assessed for eligibility and quality, and data were extracted by two independent reviewers. Overall response rates and toxicity were analyzed as dichotomous variables. Overall survival and time to progression data were analyzed as inverse variables. Meta-analyses were carried out by Review Manager 5.0 Software. This report included two large clinical trials (1973 patients) for patients with metastatic breast cancer resistant to taxanes and resistant to or pretreated with anthracyclines. Ixabepilone plus capecitabine has prolonged the median time to progression, increased overall survival and significantly increased response rates compared with capecitabine alone. Adverse events observed with the combination arm were generally manageable and well tolerated with neutropenia and febrile neutropenia, and peripheral neuropathy, myalgia, diarrhea, stomatitis and hand-foot syndrome were easily controlled. Ixabepilone plus capecitabine demonstrated clinical activity with an acceptable safety profile, which seems to be a valid option for patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054022388

Download citation: RISBibTeXText

PMID: 20146579

DOI: 10.2217/fon.09.162


Related references

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology 28(20): 3256-3263, 2010

Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting. 2007

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology 26(13): 2223-2223, 2008

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology 25(33): 5210-5217, 2007

Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology 27(13): 2185-2191, 2009

Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. Journal of Clinical Oncology 24(18_suppl): 660-660, 2016

Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. Cancer ChemoTherapy and Pharmacology 66(3): 597-603, 2010

Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer 118(2): 461-468, 2012

Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Journal of Geriatric Oncology 4(4): 346-352, 2014

Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. Clinical Breast Cancer 10(5): 352-358, 2011

Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. Onkologie 33(1-2): 53-56, 2010

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. Journal of Oncology 2012: 862921-862921, 2012

Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters 10(4): 2598-2602, 2015

Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) Quality of Life (QOL) assessment. European Journal of Cancer Supplements 6(7): 216-217, 2008

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment 117(3): 577-589, 2009